Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up
Go back to Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 61.20 +0.69 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $60.51 | 52 Week High | $77.12 | |||
| Open | $60.87 | 52 Week Low | $49.03 | |||
| Day High | $62.29 | P/E | 39.74 | |||
| Day Low | $60.68 | EPS | $1.54 | |||
| Volume | 5,993,086 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 25.10 -0.04 (0.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.14 | 52 Week High | $37.39 | |||
| Open | $25.40 | 52 Week Low | $28.25 | |||
| Day High | $25.65 | P/E | 15.21 | |||
| Day Low | $25.05 | EPS | $1.65 | |||
| Volume | 19,567,473 | |||||
